



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 18 2009

Re: XIENCE V EECSS
Docket No. FDA-2008-E-0551

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,451,233 filed by Abbott Cardiovascular Systems Inc., under 35 U.S.C. § 156. The medical device claimed by the patent is XIENCE V EECSS (everolimus eluting coronary stent system), which was assigned premarket approval application (PMA) No. 70015.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The PMA was approved on July 2, 2008, which makes the submission of the patent term extension application on July 25, 2008, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, reading "Jane A. Axelrad", is written over a faint, circular official stamp.

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

Dudas - XIENCE V EECSS

Patent No. 5,451,233

Page 2

cc: Daniel J. Hulseberg
Baker Botts LLP
Customer # 62,614
30 Rockefeller Plaza
New York, NY 10112-4498